human Mesenchymal Stem Cells for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Apr 2026: Trial registered, NCT07512362
  2. 15 May 2026: Trial started, NCT07512362

The trials

NCT07512362: Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

State
Under way
Phase
Phase 2
People
10 planned
Started
15 May 2026
Primary completion
15 Jun 2028
Arms
Mesenchymal Stem Cell Infusion
Results
None posted
  1. 6 Apr 2026: Trial registered
  2. 15 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.